Grants Available for Medical Researchers

Michael Geisman Fellowship awards to post-doctoral trainees (that is, those with an MD, DDS, DO, or PhD) who are currently working on projects with clear relevance to OI, or who have projects that will enable them to develop expertise in OI research.

A qualified applicant must hold an MD, DDS, DO, or PhD, and be appointed at the level of a post-doctoral trainee, or equivalent, within an academic institution.  An applicant should have completed their PhD or their clinical training within the past five years.  Fellowship awards provide up to $50,000 per year, which can be used for salary, fringe benefits, and supplies.  Research must be done under the supervision of a mentor with training and experience in Osteogenesis Imperfecta research or research in a related field.  Fellowship awards are for one year; a second year of funding may be approved based upon satisfactory performance during the first year of funding.  Fellowship applications require that the mentor submit a copy of his/her NIH biosketch and a letter of recommendation on behalf of the trainee, which also confirms that the mentor will supervise the trainee’s research.  Fellowship applications also require two additional letters of recommendation from scientists or clinicians who can comment upon the applicant’s training, ability, and potential to develop expertise in OI research.

The application cycle is now open. Click Here to apply. If you have any questions, please contact us at bonelink@oif.org.

Related OI Foundation Policies

Policy on Assignment and Licensing of Patents to Inventions Developed with Fellowship Grant Funding

The OI Foundation recognizes the need for and desirability of encouraging the broad utilization of the results of OI Foundation-sponsored research for the benefit of the general public, especially those affected by osteogenesis imperfecta.  Therefore, it is the intent of the OI Foundation that the benefits of any patented inventions developed through the use of OI Foundation grant money become available to those in greatest need of these innovations.

An agreement to assign inventions and patents, and to grant licenses for inventions and patents, to the OI Foundation shall be mandatory for all recipients of grant funding.  Exemptions from such agreements may be authorized in those circumstances where the mission of the OI Foundation is better served by such action.

Should the OI Foundation provide the largest proportion of grant funding for the inventor’s research which leads to the patented invention, the inventor shall assign the invention and patent to the OI Foundation.  In consideration of the assignment, the OI Foundation agrees to pay annually to the inventor, or to the inventor’s heirs, successors, or assigns, seventy-five percent (75%) of the net royalties and fees per patented invention received by the OI Foundation. Net royalties are defined as gross royalties and fees, less the costs of patenting, protecting, and preserving patents and related property rights, maintaining patents, the licensing of patents and related property rights, and such other costs, taxes, or reimbursements as may be necessary or required by law.

Upon assignment, the OI Foundation may enter into agreements with other parties for use of the patented invention in accordance with its determination of the best interests of the public.  Ordinarily, the OI Foundation will not grant rights in patented inventions to private corporations or businesses except as consistent with the best interests of the public.  In the disposition of any net income accruing to the OI Foundation from patents, first consideration shall be given to the support of research related to osteogenesis imperfecta.

Should the OI Foundation provide a lesser proportion of the inventor’s funding used in developing the patented invention, the inventor shall grant to the OI Foundation a non-exclusive, irrevocable, royalty-free license for each patent to an invention that is developed through the use of grant money furnished by the OI Foundation.

The OI Foundation asserts no claim to ownership, assignment, and/or license rights to any patent to any invention developed by a funding recipient on her/his own time, outside the scope of her/his association with the OI Foundation, and without the use of facilities, materials, or resources procured through OI Foundation funds.

Policy on Assignment and Licensing of Patents to Inventions Developed with Seed Grant Funding

The OI Foundation recognizes the need for and desirability of encouraging the broad utilization of the results of OI Foundation-sponsored research for the benefit of the general public, especially those affected by osteogenesis imperfecta.  Therefore, it is the intent of the OI Foundation that the benefits of any patented inventions developed through the use of OI Foundation grant money become available to those in greatest need of these innovations.

An agreement to assign inventions and patents, and to grant licenses for inventions and patents, to the OI Foundation shall be mandatory for all recipients of grant funding.  Exemptions from such agreements may be authorized in those circumstances where the mission of the OI Foundation is better served by such action.

Should the OI Foundation provide the largest proportion of grant funding for the inventor’s research which leads to the patented invention, the inventor shall assign the invention and patent to the OI Foundation.  In consideration of the assignment, the OI Foundation agrees to pay annually to the inventor, or to the inventor’s heirs, successors, or assigns, seventy-five percent (75%) of the net royalties and fees per patented invention received by the OI Foundation. Net royalties are defined as gross royalties and fees, less the costs of patenting, protecting, and preserving patents and related property rights, maintaining patents, the licensing of patents and related property rights, and such other costs, taxes, or reimbursements as may be necessary or required by law.

Upon assignment, the OI Foundation may enter into agreements with other parties for use of the patented invention in accordance with its determination of the best interests of the public.  Ordinarily, the OI Foundation will not grant rights in patented inventions to private corporations or businesses except as consistent with the best interests of the public.  In the disposition of any net income accruing to the OI Foundation from patents, first consideration shall be given to the support of research related to osteogenesis imperfecta.

Should the OI Foundation provide a lesser proportion of the inventor’s funding used in developing the patented invention, the inventor shall grant to the OI Foundation a non-exclusive, irrevocable, royalty-free license for each patent to an invention that is developed through the use of grant money furnished by the OI Foundation.

The OI Foundation asserts no claim to ownership, assignment, and/or license rights to any patent to any invention developed by a funding recipient on her/his own time, outside the scope of her/his association with the OI Foundation, and without the use of facilities, materials, or resources procured through OI Foundation funds.